Author Archive: AZBio

U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

Posted on by
  • This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
  • With the approval of HEMGENIX, CSL now offers an even more comprehensive portfolio of treatments for people living with hemophilia B, ushering in a new era of treatment options 

SOURCE

Continue reading→

Ultrasound activated microbubbles enhance the activity of standard of care therapeutics in pancreatic cancer

Posted on by

PHOENIX, Arizona and OSLO, Norway — November 21, 2022 — Scientists at the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, and EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a Norwegian clinical stage precision health company, today report that the ultrasound based Acoustic Cluster Therapy (ACT®) significantly enhanced the antitumor efficacy of standard care therapies in a preclinical model for pancreatic cancer.Continue reading→